Delcath Systems (DCTH) Reports Q4 Loss of $0.01/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Delcath Announces Second Quarter 2017 Financial Results
August 8, 2017 8:30 AM EDTNEW YORK, Aug. 8, 2017 /PRNewswire/ --Â Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2017.
Highlights from the second quarter of 2017 and recent weeks include:
Revenue for the second quarter of 2017 increased 20% to $0.6 million from $0.5 million in the prior-year quarter;Â Revenue for the first six months of 2017 increased 44% to $1.3 million from $0.9 million in the prior-year period; Inclusion of CHEMOSAT in Dutch Health Authorities Guidelines (published... More